DoJ weighs in on Amgen v Sandoz biosimilar clash

The US Department of Justice (DoJ) has voiced its opinion on the biosimilar dispute between Amgen and Sandoz.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

DoJ sues company for selling unapproved drugs and supplements

21 February 2017 The US Department of Justice has asked for an injunction to stop a Louisiana-based drug and dietary supplement manufacturer from distributing misbranded and unapproved new drugs and dietary supplements.

Americas

State law can’t compel ‘patent dance’, rules Federal Circuit

15 December 2017 State law cannot force drug makers to participate in the ‘patent dance’ provided for by the Biologics Price Competition and Innovation Act.

Americas

DOJ chief wades into dental antitrust case in rare intervention

9 July 2020 The antitrust chief of the US Justice Department (DOJ) made a rare appearance in court when he requested that the US Court of Appeals for the Eleventh Circuit reject a defence used by a medical and dental board against an antitrust lawsuit.

More on this story

Americas

DoJ sues company for selling unapproved drugs and supplements

Americas

State law can’t compel ‘patent dance’, rules Federal Circuit

15 December 2017 State law cannot force drug makers to participate in the ‘patent dance’ provided for by the Biologics Price Competition and Innovation Act.

Americas

DOJ chief wades into dental antitrust case in rare intervention

More on this story

Americas

DoJ sues company for selling unapproved drugs and supplements

Americas

State law can’t compel ‘patent dance’, rules Federal Circuit

15 December 2017 State law cannot force drug makers to participate in the ‘patent dance’ provided for by the Biologics Price Competition and Innovation Act.

Americas

DOJ chief wades into dental antitrust case in rare intervention